Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02884206




Registration number
NCT02884206
Ethics application status
Date submitted
25/08/2016
Date registered
30/08/2016
Date last updated
3/11/2022

Titles & IDs
Public title
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Scientific title
A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Secondary ID [1] 0 0
2016-001254-17
Secondary ID [2] 0 0
CLCZ696B2320
Universal Trial Number (UTN)
Trial acronym
PERSPECTIVE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Heart Failure (CHF) 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - LCZ696
Treatment: Drugs - Valsartan
Treatment: Drugs - Placebo of LCZ696
Treatment: Drugs - Placebo of Valsartan

Experimental: LCZ696 - Patients will receive LCZ696 at 100 mg twice daily during a single-blind treatment run-in period to ensure patients tolerate this medication before they are randomized. Down-titration is not allowed during this period. Patients who are able to tolerate LCZ696 100 mg twice daily are eligible to enter the randomized treatment period. Patients randomized to receive LCZ696 will be given LCZ696 at 200 mg twice daily. Patients will receive randomized study drug for three years.

Active Comparator: Valsartan - Patients will receive valsartan at 40mg and/or 80mg twice daily during a single-blind treatment run-in period. Following the run-in period, patients randomized to receive valsartan will be given valsartan at 160 mg twice daily for three years.


Treatment: Drugs: LCZ696
LCZ696 50, 100, and 200 mg tablets taken orally twice daily with matching placebo for valsartan

Treatment: Drugs: Valsartan
Valsartan 40, 80, and 160 mg tablets taken orally twice daily with matching placebo for LCZ696

Treatment: Drugs: Placebo of LCZ696
Placebo to match LCZ696 50 mg, 100 mg, and 200 mg tablets

Treatment: Drugs: Placebo of Valsartan
Placebo to match valsartan 40 mg, 80 mg, and 160 mg tablets
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline in the CogState Global Cognitive Composite Score (GCCS)
Timepoint [1] 0 0
Baseline, week 156
Secondary outcome [1] 0 0
Change from baseline in cortical composite standardized uptake value ratio (SUVr)
Timepoint [1] 0 0
Baseline, week 156
Secondary outcome [2] 0 0
Change from baseline in individual cognitive domains (memory, executive function, and attention)
Timepoint [2] 0 0
Baseline, week 156
Secondary outcome [3] 0 0
Change from baseline in the summary score of the instrumental activities of daily living (IADL)
Timepoint [3] 0 0
Baseline, week 156

Eligibility
Key inclusion criteria
Key

- Chronic heart failure with current symptoms NYHA class II-IV

- Left ventricular ejection fraction > 40%

- NT-proBNP >= 125 pg/mL at screening visit

- Patient with evidence of adequate functioning to complete study assessments

Key
Minimum age
60 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with acute decompensated heart failure requiring augmented therapy with
diuretics, vasodilators and/or inotropic drugs

- Acute coronary syndrome (including myocardial infarction (MI)), cardiac surgery, other
major CV surgery, or urgent percutaneous coronary intervention (PCI), carotid surgery
or carotid angioplasty, history of stroke or transient ischemic attack within the 3
months prior to Screening visit or an elective PCI within 30 days prior to Screening
visit

- Patients with history of hereditary or idiopathic angioedema or angioedema related to
previous ACEi or ARB therapies

- Patients who require treatment with 2 or more of the following: an ACEi, an ARB or a
renin inhibitor

- Patients with one of the following:

1. Patients with serum potassium >5.2 mmol/L (mEq/L) at Screening visit

2. Patients with serum potassium >5.4 mmol/L (mEq/L) at any visit during run-in
treatment period or at randomization visit

3. Systolic blood pressure (SBP) =180 mmHg at Screening visit, or

4. SBP <110 mmHg at Screening visit, or

5. SBP <100 mmHg or symptomatic hypotension as determined by the investigator at
Visit 103 or at randomization visit

6. Body mass index (BMI) >45 kg/m^2

- Patients with

1. known pericardial constriction, genetic hypertrophic cardiomyopathy, infiltrative
cardiomyopathy

2. hemodynamically significant obstructive valvular disease

- Life-threatening or uncontrolled dysrhythmia, including symptomatic or sustained
ventricular tachycardia and atrial fibrillation or flutter with a resting ventricular
rate >110 beats per minute

- Inability to perform cognitive battery or other study evaluations based on significant
motor (e.g. hemiplegia, muscular-skeletal injury) or sensory (blindness, decreased or
uncorrected visual or auditory acuity) skill

- Clinically significant cerebral pathology for example large cerebral aneurysm or space
occupying lesion that may impact cognition as assessed by central MRI reader

- Mini mental state examination score less than 24 at screening

- Patients with a clinical diagnosis of Alzheimer's disease or other dementia syndromes
or any indication for or current treatment with cholinesterase inhibitors and/or
another prescription AD treatment (e.g. memantine).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/11/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
16/05/2022
Sample size
Target
Accrual to date
Final
592
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Chemside
Recruitment hospital [2] 0 0
Novartis Investigative Site - Milton
Recruitment hospital [3] 0 0
Novartis Investigative Site - Bedford Park
Recruitment hospital [4] 0 0
Novartis Investigative Site - Geelong
Recruitment postcode(s) [1] 0 0
4032 - Chemside
Recruitment postcode(s) [2] 0 0
4064 - Milton
Recruitment postcode(s) [3] 0 0
5042 - Bedford Park
Recruitment postcode(s) [4] 0 0
3220 - Geelong
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Montana
Country [13] 0 0
United States of America
State/province [13] 0 0
Nevada
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Washington
Country [22] 0 0
Argentina
State/province [22] 0 0
ARG
Country [23] 0 0
Argentina
State/province [23] 0 0
Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Capital Federal
Country [25] 0 0
Belgium
State/province [25] 0 0
Aalst
Country [26] 0 0
Bulgaria
State/province [26] 0 0
BGR
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Sofia
Country [28] 0 0
Canada
State/province [28] 0 0
Ontario
Country [29] 0 0
Canada
State/province [29] 0 0
Quebec
Country [30] 0 0
Croatia
State/province [30] 0 0
Rijeka
Country [31] 0 0
Croatia
State/province [31] 0 0
Zagreb
Country [32] 0 0
France
State/province [32] 0 0
Paris
Country [33] 0 0
France
State/province [33] 0 0
Tourcoing
Country [34] 0 0
Germany
State/province [34] 0 0
Bavaria
Country [35] 0 0
Germany
State/province [35] 0 0
Sachsen
Country [36] 0 0
Germany
State/province [36] 0 0
Berlin Buch
Country [37] 0 0
Germany
State/province [37] 0 0
Berlin
Country [38] 0 0
Germany
State/province [38] 0 0
Bielefeld
Country [39] 0 0
Germany
State/province [39] 0 0
Bitburg
Country [40] 0 0
Germany
State/province [40] 0 0
Dessau-Roßlau
Country [41] 0 0
Germany
State/province [41] 0 0
Dresden
Country [42] 0 0
Germany
State/province [42] 0 0
Elsterwerda
Country [43] 0 0
Germany
State/province [43] 0 0
Frankfurt
Country [44] 0 0
Germany
State/province [44] 0 0
Koeln
Country [45] 0 0
Germany
State/province [45] 0 0
Ulm
Country [46] 0 0
Germany
State/province [46] 0 0
Wuerzburg
Country [47] 0 0
Germany
State/province [47] 0 0
Wuppertal
Country [48] 0 0
Italy
State/province [48] 0 0
AN
Country [49] 0 0
Italy
State/province [49] 0 0
BG
Country [50] 0 0
Italy
State/province [50] 0 0
FE
Country [51] 0 0
Italy
State/province [51] 0 0
FI
Country [52] 0 0
Italy
State/province [52] 0 0
IS
Country [53] 0 0
Italy
State/province [53] 0 0
MI
Country [54] 0 0
Italy
State/province [54] 0 0
MO
Country [55] 0 0
Italy
State/province [55] 0 0
PI
Country [56] 0 0
Korea, Republic of
State/province [56] 0 0
Gangwon-Do
Country [57] 0 0
Korea, Republic of
State/province [57] 0 0
Gyeonggi Do
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Korea
Country [59] 0 0
Lithuania
State/province [59] 0 0
LTU
Country [60] 0 0
Lithuania
State/province [60] 0 0
Vilnius
Country [61] 0 0
Netherlands
State/province [61] 0 0
Amsterdam
Country [62] 0 0
Netherlands
State/province [62] 0 0
Hertogenbosch
Country [63] 0 0
Poland
State/province [63] 0 0
Lodzkie
Country [64] 0 0
Poland
State/province [64] 0 0
Malopolskie
Country [65] 0 0
Poland
State/province [65] 0 0
Maloposkie
Country [66] 0 0
Poland
State/province [66] 0 0
Bialystok
Country [67] 0 0
Poland
State/province [67] 0 0
Katowice
Country [68] 0 0
Poland
State/province [68] 0 0
Krakow
Country [69] 0 0
Poland
State/province [69] 0 0
Warszawa
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Moscow
Country [71] 0 0
Russian Federation
State/province [71] 0 0
Saint Petersburg
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Saratov
Country [73] 0 0
Russian Federation
State/province [73] 0 0
St Petersburg
Country [74] 0 0
Spain
State/province [74] 0 0
Comunidad Valenciana
Country [75] 0 0
Spain
State/province [75] 0 0
Madrid
Country [76] 0 0
Spain
State/province [76] 0 0
Valencia
Country [77] 0 0
Spain
State/province [77] 0 0
Zaragoza
Country [78] 0 0
Switzerland
State/province [78] 0 0
Basel
Country [79] 0 0
Taiwan
State/province [79] 0 0
Tainan
Country [80] 0 0
Taiwan
State/province [80] 0 0
Taipei
Country [81] 0 0
Turkey
State/province [81] 0 0
Eskisehir
Country [82] 0 0
Turkey
State/province [82] 0 0
Sivas
Country [83] 0 0
United Kingdom
State/province [83] 0 0
Somerset
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Wales
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Birmingham
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Bournemouth
Country [87] 0 0
United Kingdom
State/province [87] 0 0
East Yorkshire
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Harrow
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Liverpool
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Newport
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Stevenage

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the effect of LCZ696 compared to valsartan on
cognitive function in patients with chronic heart failure and preserved ejection fraction.
Cognitive function will be assessed using a comprehensive battery of tests with an evaluation
of longitudinal change of cognitive domains including memory, executive function, and
attention.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02884206
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02884206